Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
27 9월 2024 - 5:45AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
SCHEDULE
13G/A
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT
NO. 1)
RESHAPE
LIFESCIENCES INC.
(Name
of Issuer)
COMMON
STOCK, $0.001 PAR VALUE PER SHARE
(Title
of Class of Securities)
76090R101
(CUSIP
Number)
September
23, 2024
(DATE
OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)
Check the
appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(c)
* | The
remainder of this cover page shall be filled out for a reporting person’s initial filing
on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in a prior cover page. |
The information
required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).
(Continued
on following page(s))
CUSIP
No.76090R101 |
|
13G/A |
Page 2 of 5 Pages |
1. |
NAMES
OF REPORTING PERSON
S.S.
OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Yair
Schneid |
2. |
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
(a)
☐
(b)
☐ |
3. |
SEC
USE ONLY
|
4. |
CITIZENSHIP
OR PLACE OF ORGANIZATION
USA |
5. |
SOLE VOTING POWER,
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON – 37,407 Shares (1)(2) |
|
|
6. |
SHARED
VOTING POWER – None |
|
|
7. |
SOLE
DISPOSITIVE POWER – 37,407 Shares (1)(2) |
|
|
8. |
SHARED
DISPOSITIVE POWER – None |
|
|
9. |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON – |
|
|
|
37,407
Shares (1)(2) |
10. |
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
|
|
|
☐ |
11. |
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
|
|
|
8.374% |
12. |
TYPE
OF REPORTING PERSON |
|
|
|
IN
|
(1) | Based
on 29,387,152 (pre-split) shares outstanding as of August 12, 2024 as reported in Form 10-Q
for the quarter ended June 30, 2024 filed with the Securities and Exchange Commission on
August 14, 2024. |
| |
(2) | Reporting Person's holdings are based on the Issuer's post-split shares of 1 for 58. |
CUSIP
No.76090R101 |
|
13G/A |
Page 3 of 5 Pages |
ITEM 1 | (a)
NAME OF ISSUER: Reshape Lifesciences Inc. |
ITEM 1 | (b)
ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES: |
| |
| 1001
Calle Amanecer, San Clemente, CA 92673 |
ITEM 2 | (a)
NAME OF PERSON FILING: Yair Schneid |
ITEM 2 | (b)
ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: |
| |
| 1 Wood
Lane, Suffern, NY 10901 |
ITEM 2 | (c)
CITIZENSHIP: USA |
ITEM 2 | (d)
TITLE OF CLASS OF SECURITIES: Common Shares, $0.001 par value per share |
ITEM 2 | (e)
CUSIP NUMBER: 76090R101 |
ITEM 3 | IF
THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B): Not applicable |
ITEM 4 | OWNERSHIP |
| |
| (a)
AMOUNT BENEFICIALLY OWNED: 37,407 Shares (1)(2) |
| |
| (b)
PERCENT OF CLASS: 8.374% |
| |
| (c)
NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS: |
| |
| (i)
SOLE POWER TO VOTE OR DIRECT THE VOTE |
| |
| 37,407
Shares (1)(2) |
| |
| (ii)
SHARED POWER TO VOTE OR DIRECT THE VOTE |
| |
| 0
Shares |
| |
| (iii)
SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF |
| |
| 37,407
Shares (1)(2) |
| |
| (iv)
SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF |
| |
| 0
Shares |
CUSIP
No.76090R101 |
|
13G/A |
Page 4 of 5 Pages |
ITEM 5 | OWNERSHIP
OF FIVE PERCENT OR LESS OF A CLASS |
Not
applicable
ITEM 6 | OWNERSHIP
OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON |
Not
applicable
ITEM
7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
Not
applicable
ITEM 8 | IDENTIFICATION
AND CLASSIFICATION OF MEMBERS OF A GROUP |
Not
applicable
ITEM 9 | NOTICE
OF DISSOLUTION OF GROUP |
Not
applicable
CUSIP
No.76090R101 |
|
13G/A |
Page 5 of 5 Pages |
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.
|
September
26, 2024 |
|
(Date) |
|
|
|
/s/
Yair Schneid |
|
(Signature) |
|
|
|
Yair
Schneid |
|
(Name/Title) |
ReShape Lifesciences (NASDAQ:RSLS)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
ReShape Lifesciences (NASDAQ:RSLS)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024